Get the Stockscreener App
9.77
0.31%
0.03
Embecta Corp stock is traded at $9.77, with a volume of 1.27M.
It is up +0.31% in the last 24 hours and down -20.50% over the past month.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
See More
Previous Close:
$9.74
Open:
$9.84
24h Volume:
1.27M
Relative Volume:
2.12
Market Cap:
$592.02M
Revenue:
$1.12B
Net Income/Loss:
$55.30M
P/E Ratio:
10.28
EPS:
0.95
Net Cash Flow:
$-30.30M
1W Performance:
+2.20%
1M Performance:
-20.50%
6M Performance:
-51.71%
1Y Performance:
-21.59%
1-Day Range:
$9.61
$9.91
1-Week Range:
$9.49
$10.29
52-Week Range:
$9.49
$21.48
Embecta Corp Stock (EMBC) Company Profile
Name
Embecta Corp
Sector
Industry
Phone
(862) 401-0000
Address
1209 ORANGE STREET, WILMINGTON
Compare EMBC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EMBC
Embecta Corp
|
9.77 | 592.02M | 1.12B | 55.30M | -30.30M | 0.95 |
|
ISRG
Intuitive Surgical Inc
|
509.36 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
168.42 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.40 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
253.68 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
215.82 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Embecta Corp Stock (EMBC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Nov-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-08-22 | Initiated | BTIG Research | Neutral |
| Aug-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-22 | Initiated | BofA Securities | Underperform |
View All
Embecta Corp Stock (EMBC) Latest News
Embecta raises adjusted EBITDA margin outlook for FY 2025 amid restructuring and debt reduction - MSN
Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR | MarketsandMarkets™NORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
Transcript : Embecta Corp. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - MarketScreener
InvestingPro’s bearish call on Embecta proves accurate with 48% decline By Investing.com - Investing.com Nigeria
Embecta stock hits 52-week low at $10.26 amid market challenges By Investing.com - Investing.com South Africa
Embecta stock hits 52-week low at $10.26 amid market challenges - Investing.com Australia
BofA cuts Embecta stock price target to $18 from $20 By Investing.com - Investing.com South Africa
BofA cuts Embecta stock price target to $18 from $20 - Investing.com India
(EMBC) Technical Data - news.stocktradersdaily.com
Embecta Corp (EMBC) Stock Price Down 6.22% on May 28 - GuruFocus
embecta to Participate in Investor Events - The Manila Times
embecta to Participate in Investor Events - GlobeNewswire Inc.
Independent Non-Executive Chairman of Embecta Picks Up 13% More Stock - Yahoo Finance
Insider Buying: David Melcher Acquires 10,000 Shares of Embecta Corp (EMBC) - GuruFocus
Director Makes Bold Move with Major Stock Purchase in Embecta Corporation! - TipRanks
Embecta (EMBC): Mizuho Maintains Rating, Adjusts Price Target | - GuruFocus
Embecta (EMBC): Mizuho Maintains Rating, Adjusts Price Target | EMBC Stock News - GuruFocus
Embecta (EMBC) Price Target Cut by Mizuho Amid Flat Sales Outlook | EMBC Stock News - GuruFocus
Embecta price target lowered to $25 from $26 at BTIG - TipRanks
Embecta Corporation’s Strategic Transition and Financial Outlook: A Buy Rating Based on Growth Initiatives and Attractive Valuation - TipRanks
Embecta Corp (EMBC) Shares Gap Down to $10.85 on May 22 - GuruFocus
Embecta stock touches 52-week low at $10.82 amid market challenges - Investing.com Australia
Embecta eyes shift from insulin delivery to broader medical supplies focus - Drug Delivery Business
Transcript : Embecta Corp.Analyst/Investor Day - marketscreener.com
Embecta stock touches 52-week low at $10.82 amid market challenges By Investing.com - Investing.com South Africa
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15 - simplywall.st
Embecta Unveils Strategy at Analyst and Investor Day - TipRanks
Embecta (NASDAQ:EMBC) Has Affirmed Its Dividend Of $0.15 - Yahoo Finance
Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025 - marketscreener.com
embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day - The Manila Times
Embecta Corp. Hosts Inaugural Analyst and Investor Day to Outline Long-Term Financial Plan and Strategic Priorities - Nasdaq
embecta to Showcase Phased Approach for Value Creation and - GlobeNewswire
embecta recognized as Healthcare Technology Company of the Year - The Healthcare Technology Report.
Cautious Outlook on Embecta Corporation Amidst Unclear Growth Catalysts and Margin Concerns - TipRanks
Embecta Corp (EMBC) Shares Down 2.83% on May 19 - GuruFocus
How to Take Advantage of moves in (EMBC) - news.stocktradersdaily.com
Embecta Corp. (NASDAQ:EMBC) Q2 2025 Earnings Call Transcript - MSN
Embecta: Not Nearly As Cheap As The 4x Forward P/E Ratio Would Imply (NASDAQ:EMBC) - Seeking Alpha
Embecta restructures again, outlines tariff costs - MedTech Dive
Morgan Stanley Adjusts Price Target on Embecta to $15 From $20, Maintains Equalweight Rating - marketscreener.com
Positive Outlook for Embecta Corporation Amid Strong Financial Performance and Strategic Initiatives - TipRanks
Cautious Optimism for Embecta Corporation Amid Challenging Environment and Hold Rating - TipRanks
Embecta Q2 2025 slides: Revenue decline offset by margin improvement and debt reduction - Investing.com
Earnings call transcript: Embecta Q2 2025 beats EPS forecast, stock dips - Investing.com Nigeria
Embecta Corp Stock (EMBC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Embecta Corp Stock (EMBC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Melcher David F | Director |
Feb 25 '25 |
Buy |
13.67 |
13,000 |
177,646 |
76,681 |
| Morris Milton Mayo | Director |
Feb 13 '25 |
Sale |
16.38 |
3,100 |
50,783 |
36,133 |
1.29%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):